Private Market View

Xiangsheng Technology (Pharmaceuticals)

Nanjing, China · Founded 2023 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include CAS Star, Addor Capital, Innoangel Fund, Goldport Capital, Suzhou Angel Fund of Funds6 tracked in total.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 6 names
  • ·Watchlist + deal alerts for Xiangsheng Technology (Pharmaceuticals)
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Xiangsheng Technology (Pharmaceuticals) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Xiangsheng Technology (Pharmaceuticals)

Manufacturer of bio-based and high-performance materials intended for industries seeking high-performance, sustainable materials for applications in biotechnology, electronics, and advanced manufacturing. The company offers intelligent microfluidic manufacturing of advanced materials, supported by academic research platforms, thereby enabling clients to gain access to research-driven, scalable production technologies.

Sector
Healthcare
HQ
Nanjing, China
Founded
2023
Ownership
Privately Held (backing)
PA Mark — not yet priced

Xiangsheng Technology (Pharmaceuticals) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Xiangsheng Technology (Pharmaceuticals) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Xiangsheng Technology (Pharmaceuticals) in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.